Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 6/20 | 0.46 |
| ▸ | FLT4 | P35916 | 5/20 | 0.46 |
| ▸ | FLT3 | P36888 | 5/20 | 0.46 |
| ▸ | KIT | P10721 | 5/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 4/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.46 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340707 | 0.90 | KDM4E (0.54) | KDM4EGAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7639538 | 0.84 | KDM4E (0.49) | KDM4EGAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL16226095 | 0.84 | KDM4E (0.56) | KDM4EGAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL23599375 | 0.81 | MAOA (0.40) | KDM4EGAASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL12261421 | 0.80 | KDM4E (0.45) | KDM4EGAASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL1274286 | 0.80 | ALDH1A1 (0.55) | KDM4EGAAALDH1A1GLAELANE | |
| SCHEMBL29385499 | 0.80 | KDM4E (0.45) | KDM4EGAASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL4179706 | 0.79 | PBRM1 (0.44) | SMN1; SMN2ALDH1A1MAPTCYP3A4 | |
| SCHEMBL12310550 | 0.79 | TUBB4A (0.39) | KDM4EGAASMN1; SMN2ALDH1A1GLA | |
| SCHEMBL21098798 | 0.79 | MAOA (0.38) | KDM4EGAASMN1; SMN2ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | Jubilant Prodel LLC | 2022-12-20 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC | 2021-01-21 | — | — | US | disclosed |
| EP-3765453-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | Jubilant Prodel LLC (US) | 2021-01-20 | — | — | EP | disclosed |
| CN-112105610-A | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2020-12-18 | — | — | CN | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| WO-2019175897-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | JUBILANT BIOSYS LIMITED (IN) | 2019-09-19 | — | — | WO | disclosed |
| WO-2004011446-A1 | INDANE, DIHYDROBENZOFURAN, AND TETRAHYDRONAPHTHALENE CARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIDIABETICS | BAYER PHARMACEUTICALS CORPORATION (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015810-A1 | BICYCLIC COMPOUNDS AS INHIBITORS OF PD1/PD-L1 INTERACTION/ACTIVATION | CD274, PDCD1, PDCD1LG2 | KDM4E 2775/4885GAA 1553/4885SMN1; SMN2 2891/4885 |
| US-11529341-B2 | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | CD274, PDCD1, PDCD1LG2 | KDM4E 2775/4885GAA 1553/4885SMN1; SMN2 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.